Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity
about
Multi-Facial, Non-Peptidic α-Helix MimeticsDirect and Propagated Effects of Small Molecules on Protein-Protein Interaction NetworksSmall Molecule Targeting of Protein-Protein Interactions through Allosteric Modulation of DynamicsExpanding the number of 'druggable' targets: non-enzymes and protein-protein interactionsOrganization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase ComplexIs NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein InteractionProperty Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)Smart surface for elution of protein-protein bound particles: nanonewton dielectrophoretic forces using atomic layer deposited oxidesStructural determinants of Tau aggregation inhibitor potencyNMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexesInhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes.Essential multimeric enzymes in kinetoplastid parasites: A host of potentially druggable protein-protein interactions.Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Structural basis of IL-23 antagonism by an Alphabody protein scaffoldProtein engineering of the N-terminus of NEMO: structure stabilization and rescue of IKKβ binding.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein.Structure and mechanism of action of tau aggregation inhibitors.Development of a capillary electrophoresis platform for identifying inhibitors of protein-protein interactionsStructure-based design of small-molecule protein-protein interaction modulators: the story so far.Challenges and opportunities in targeting the menin-MLL interaction.Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.Alternative modulation of protein-protein interactions by small moleculesA Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of InfluenzaTargeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction SitesState-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix.Towards more drug-like proteomimetics: two-faced, synthetic α-helix mimetics based on a purine scaffold.Genome and network visualization facilitates the analyses of the effects of drugs and mutations on protein-protein and drug-protein networks.Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand ComplexesSwa2, the yeast homolog of mammalian auxilin, is specifically required for the propagation of the prion variant [URE3-1].Structural Insights into the Tetrameric State of Aspartate-β-semialdehyde Dehydrogenases from Fungal Species.Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactions.Module assembly for designing multivalent mid-sized inhibitors of protein-protein interactions.An overview of the neurobiology of suicidal behaviors as one meta-system.The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics.Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions.
P2860
Q26781261-2D97B807-D999-4C96-A4D6-47C656D6D7DFQ26784027-CA38EB71-7164-4E05-8C2C-AFF83A35EDFEQ26785992-6872E8E3-3ED3-4C26-928D-51B0FC94187AQ27003966-764AAA92-E2C5-48DF-B613-2B8A74E69586Q27468732-914ECB36-950D-48B5-95E1-70FB23E7F302Q27681373-36984B4E-A8E4-420A-BCA8-7F4843B9847DQ27681486-1A510FBE-7E36-4141-AF32-3E98C3626DBFQ27703522-A4BCD7D9-3014-4998-BEB9-A9B341C4DB62Q28830310-CF390487-CFCC-47E5-9BB2-45F4F8B032D8Q30353954-9BD2E907-C4CA-4D80-B5EC-A1133C0D5B59Q30366295-351DDEC0-69A5-45A1-85CC-EA7675D61266Q30546915-130773C8-5A34-4732-A647-8D4C7CF61B61Q33898663-EA7BEABC-C77C-44DE-9D22-682B9C57DDEDQ34263719-75524685-52FE-44A7-B2E2-937878B85BE8Q34445379-23A22919-8681-4016-8339-515A8F361E94Q34463911-A1A4E72F-0EAE-4358-A99B-643F36A994CCQ34495028-F976D23E-E983-4808-B0EE-26C6E4775F13Q34777828-BA034D8B-885E-453D-887A-ABDAAAACBC3AQ34902096-6CD594DD-0F12-4627-B371-247F68C9D8ECQ34995711-11C7E624-D27F-4727-BD08-3957209FFFACQ35103944-07CA3897-F285-4F0D-910F-9CEDA6268B1BQ35122366-5002FFE0-7D18-4A83-A568-2FDF17B3C9EAQ35397776-FE0C996F-0BF8-4F77-95EC-A83C7B022209Q35620999-244BDECD-4069-4BBF-8F7F-C8A8DCDE6C85Q35669847-4BA04774-B103-4AF5-ACA2-F0503E62AD88Q35687836-5BA61F87-5B5D-49A0-A481-3A7D9245AE27Q35693426-F8AFF520-A9AC-43AE-AB02-0CA6227FB7D5Q35738960-16AE2CFE-BD3F-4FE0-A306-5AE91B41D06AQ35781290-9114CF88-FFA9-4449-AB53-61BA64C7518AQ35926303-0292F728-74C3-4775-98B1-DB73890C5628Q35951692-C4B7B21B-370D-49D4-A603-1BE1BE793DBEQ35981250-B286842F-5F6E-4254-8D2A-AFDA4374902CQ36096683-E0CF33E2-9901-4564-9B98-84FA80D7E270Q36399121-EBED2CDF-B169-4159-ABD5-CE5DDE95F798Q36574493-E57A44F5-6D92-4B55-935B-09248EF20E1AQ38164841-7D2BC64B-0FB0-4CB5-83A1-2977CAC19B17Q38168810-4F707873-7EB3-4A26-8732-DFE6FBC4A74EQ38245264-7C94B369-6FEE-4583-8522-E6C67C063CCDQ38510112-E55FF0FE-5771-4AC1-B1A3-E2D091025ABFQ38563691-4563CA0E-AB0C-43F9-8E69-6751155444CF
P2860
Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Features of protein-protein in ...... ogy, surface area and affinity
@ast
Features of protein-protein in ...... ogy, surface area and affinity
@en
Features of protein-protein in ...... ogy, surface area and affinity
@nl
type
label
Features of protein-protein in ...... ogy, surface area and affinity
@ast
Features of protein-protein in ...... ogy, surface area and affinity
@en
Features of protein-protein in ...... ogy, surface area and affinity
@nl
prefLabel
Features of protein-protein in ...... ogy, surface area and affinity
@ast
Features of protein-protein in ...... ogy, surface area and affinity
@en
Features of protein-protein in ...... ogy, surface area and affinity
@nl
P2860
P3181
P356
P1476
Features of protein-protein in ...... ogy, surface area and affinity
@en
P2093
Jason E. Gestwicki
Matthew C. Smith
P2860
P3181
P356
10.1017/ERM.2012.10
P407
P577
2012-07-26T00:00:00Z